Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ (2013) 2.26

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail (2013) 1.29

Carvedilol in the treatment of elderly patients with chronic heart failure. Clin Interv Aging (2008) 0.77

Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date. Drug Des Devel Ther (2016) 0.75

Analysis Treatment Guideline versus Clinical Practice Protocol in Patients Hospitalized due to Heart Failure. Arq Bras Cardiol (2016) 0.75

Decrease in plasma cyclophilin A concentration at 1 month after myocardial infarction predicts better left ventricular performance and synchronicity at 6 months: a pilot study in patients with ST elevation myocardial infarction. Int J Biol Sci (2015) 0.75

A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure. Clin Med Insights Cardiol (2016) 0.75

Factors associated with β-blocker initiation and discontinuation in a population-based cohort of seniors newly diagnosed with heart failure. Patient Prefer Adherence (2016) 0.75

Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine. Am J Cardiovasc Drugs (2016) 0.75

Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. Circ Heart Fail (2017) 0.75

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord (2017) 0.75

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Universal definition of myocardial infarction. Circulation (2007) 11.69

Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med (2006) 10.65

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 9.80

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75

Effusive-constrictive pericarditis. N Engl J Med (2004) 5.82

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79

Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet (2002) 5.77

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J (2013) 5.23

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA (2005) 4.46

Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation (2005) 3.96

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89

Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71

Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med (2005) 3.52

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50

Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J (2004) 3.45

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 3.40

N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med (2005) 3.35

Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med (2005) 3.30

The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J (2004) 3.27

Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation (2005) 2.81

Gender differences in the management and clinical outcome of stable angina. Circulation (2006) 2.59

Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis (2007) 2.47

World Health Organization definition of myocardial infarction: 2008-09 revision. Int J Epidemiol (2010) 2.38

Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J (2007) 2.17

Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart (2007) 2.05

[Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin]. Ugeskr Laeger (2008) 2.03

High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. J Hypertens (2006) 2.03

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J (2013) 1.92

Long-term follow-up of aortic intramural hematoma: predictors of outcome. Circulation (2003) 1.90

Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med (2009) 1.85

Comparison of outcome and complications using different types of devices for percutaneous closure of a secundum atrial septal defect in adults: a single-center experience. Catheter Cardiovasc Interv (2006) 1.85

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ (2005) 1.84

Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens (2007) 1.77

Lessons from the first patient with an implanted pacemaker: 1958-2001. Pacing Clin Electrophysiol (2003) 1.76

The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther (2004) 1.70

A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J (2011) 1.67

Effect of inhibition of Na(+)/Ca(2+) exchanger at the time of myocardial reperfusion on hypercontracture and cell death. Cardiovasc Res (2002) 1.67

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol (2008) 1.67

Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J (2008) 1.65

Prognostic value of clinical and morphologic findings in short-term evolution of aortic intramural haematoma. Therapeutic implications. Eur Heart J (2004) 1.64

The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina. Eur Heart J (2005) 1.64

Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens (2013) 1.62

Extracorporeal pulmonary support in severe pulmonary failure in adults: a treatment rediscovered. Dtsch Arztebl Int (2013) 1.61

Predicting prognosis in stable angina--results from the Euro heart survey of stable angina: prospective observational study. BMJ (2006) 1.61

A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study. Eur J Heart Fail (2009) 1.61

The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J (2009) 1.60

The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J (2005) 1.58

Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol (2007) 1.58

Diagnosis and management of pericardial effusion. World J Cardiol (2011) 1.57

A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol (2006) 1.57

Prognostic value of lead aVR in patients with a first non-ST-segment elevation acute myocardial infarction. Circulation (2003) 1.54

Time course of eosinophilic myocarditis visualized by CMR. J Cardiovasc Magn Reson (2008) 1.53

Prehospital troponin T testing in the diagnosis and triage of patients with suspected acute myocardial infarction. Am J Cardiol (2011) 1.52

Familial hypertrophic cardiomyopathy: the same mutation, different prognosis. Comparison of two families with a long follow-up. Rev Port Cardiol (2003) 1.50

Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol (2005) 1.47

Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology (2008) 1.47

Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease? Am Heart J (2006) 1.45

Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. Am Heart J (2002) 1.43

Migraine with aura related to the percutaneous closure of an atrial septal defect. Catheter Cardiovasc Interv (2003) 1.42

Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J (2003) 1.41

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation (2007) 1.41

The need for resources for clinical research: the European Society of Cardiology calls for European, international collaboration. Lancet (2002) 1.41

Paroxysmal atrial fibrillation is uncommon in outpatients with chronic heart failure. Scand Cardiovasc J (2008) 1.40

Fluvastatin reduces cardiac mortality in patients with coronary heart disease. Cardiovasc Drugs Ther (2004) 1.40

Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial. Arch Cardiovasc Dis (2009) 1.39

[Evolution of systolic function and myocardial perfusion, evaluated by gated-SPECT, in the first year after acute myocardial infarction]. Rev Esp Cardiol (2003) 1.39

[Methods of reporting research-results and their influence on decision-making by cardiologists prescribing drugs for primary and secondary prevention]. Rev Esp Cardiol (2002) 1.39

Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol (2004) 1.38

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res (2004) 1.37

Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J (2007) 1.32

N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension (2005) 1.31

Long-term effects of lifestyle behavior change in coronary artery disease: effects on recurrent coronary events after percutaneous coronary intervention. Health Psychol (2005) 1.29

The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J (2005) 1.28

Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J (2009) 1.26

Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart (2006) 1.26

Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol (2004) 1.24

Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res (2002) 1.23

The universal definition of myocardial infarction: a consensus document: ischaemic heart disease. Heart (2008) 1.21

Myocardial infarction with normal coronary arteries: ten-year follow-up. Ital Heart J (2004) 1.17

Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev (2004) 1.17

Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial. Heart (2013) 1.17

Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med (2013) 1.16

Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy. Hum Mol Genet (2012) 1.16

Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care (2003) 1.15

Third universal definition of myocardial infarction. Glob Heart (2012) 1.14